research use only

Domperidone Dopamine Receptor inhibitor

Name: Domperidone
Brand: Selleck Chemicals
SKU: S2461
Availability: InStock
Rating: 5 (4 reviews)

Cat.No.S2461

Domperidone is an oral dopamine D2 receptor antagonist, used to treat nausea and vomiting. This compound acts by blocking dopamine receptors, which helps to reduce symptoms of gastrointestinal distress. It is often prescribed for its antiemetic effects.

Chemical Structure

Molecular Weight: 425.91

Jump to

Quality Control

Batch: Purity: 99.92%

99.92

Related Targets	Adrenergic Receptor AChR 5-HT Receptor COX Calcium Channel Histamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE) GluR
Other Dopamine Receptor Inhibitors	MPTP Hydrochloride Trifluoperazine Trifluoperazine 2HCl Penfluridol Rotundine Sulpiride Azaperone ONC206 SCH-23390 hydrochloride Levosulpiride

Solubility

In vitro
Batch:

DMSO : 48 mg/mL (112.69 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 1 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	4.25mg/ml (9.98mM)	Taking the 1 mL working solution as an example, add 50 μL of 85 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	425.91	Formula	C₂₂H₂₄ClN₅O₂	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	57808-66-9	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			SMILES	C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	Dopamine D2 receptor
In vitro	Domperidone (a D2R antagonist) inhibits Equilibrative NT1 (ENT1) activity more in the presence than in the absence of Bromocriptine and displays an IC50 value lower than that of Bromocriptine or Ergovaline in Madin-Darby bovine kidney (MDBK) cells.
In vivo	Domperidone (0.1 mg/kg) results in a significant decrease in feeding behavior and stimulation of basal metabolism, but has no effect on locomotor activity of rats in a Phenomaster system. This compound (1.1 mg/kg and 5.5 mg/kg, oral) significantly increases laminar microvascular blood flow (LMBF) in horses, compared with baseline values, beginning 4 hours after administration, and this effect persisted for at least 8 hours. It (0.2 mg/kg, i.v.) significantly increases laminar microvascular blood flow (LMBF) in horses, compared with baseline values, at 10 and 12 hours after administration. This chemical can ameliorate deleterious reproductive effects and reduce weight gain associated with fescue toxicosis in heifers. Domperidone-treated mares have shorter gestation duration and foaled closer to their expected parturition date than did control mares. They have higher Mammary gland scores and serum prolactin concentration. It (5 mg/kg, oral) increases peak plasma acetaminophen concentration and area under the curve in rats, indicating increased gastric emptying. This compound decreases the dopamine-induced contractile activity of midjejunal longitudinal muscle strips in rats.
References	[1] https://pubmed.ncbi.nlm.nih.gov/21790119/ [2] https://pubmed.ncbi.nlm.nih.gov/24288745/ [3] https://pubmed.ncbi.nlm.nih.gov/20187829/ [4] https://pubmed.ncbi.nlm.nih.gov/14552385/ [5] https://pubmed.ncbi.nlm.nih.gov/8067624/ [6] https://pubmed.ncbi.nlm.nih.gov/23879848/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-03-24)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04699591	RECRUITING	GERD; Gastroesophageal Reflux; Gastroparesis	Jose Cocjin	2013-04
NCT06695962	NOT_YET_RECRUITING	Type 1 Diabetic	University Hospital, Rouen	2026-03-01	PHASE3
NCT01696734	RECRUITING	Digestive System Disorder; Dyspepsia; Esophagitis; Gastroesophageal Reflux Disease; Gastroparesis; Heartburn; Nausea and Vomiting	M.D. Anderson Cancer Center	2012-10-23	PHASE3
NCT07578402	NOT_YET_RECRUITING	Dyspepsia; Functioanl Dyspepsia; Epigastric Pain Syndrome; Epigastric Fullness	Rakibul Mostafa	2026-05-15	PHASE4
NCT06590805	RECRUITING	Physical Therapy; Electrotherapy; Dietary Modification	Haytham Ibrahim Morsi	2024-09-01
NCT05570292	COMPLETED	Gastric Residual Volume	Ain Shams University	2022-10-10	PHASE3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):